The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Hypertension, Portal
Interventions
DRUG

Alverine

180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks

DRUG

Carvedilol

taken orally, starting dose of 6.25 mg once a day, gradually adjusted according to heart rate to 6.25 mg twice a day, 12.5 mg in the morning and 6.25 mg in the evening, 12.5 mg twice a day, or adjusted to the maximum tolerated dose (heart rate greater than 55 beats/min and systolic blood pressure greater than 90 mmHg), taken continuously for 24 weeks.

All Listed Sponsors
collaborator

Shandong Provincial Hospital

OTHER_GOV

collaborator

Shanghai East Hospital

OTHER

collaborator

Shanghai Zhongshan Hospital

OTHER

collaborator

Affiliated Drum Tower Hospital of Nanjing University Medical School

UNKNOWN

collaborator

The First Affiliated Hospital of Nanchang University

OTHER

collaborator

Shanghai Public Health Clinical Center

OTHER_GOV

collaborator

Daping Hospital, Army Medical Center of PLA

OTHER

lead

Shanghai Changzheng Hospital

OTHER